SCHEMBL3551865

SCHEMBL3551865

CCOc1cc(C(CC(=O)NOC(=O)CC(C)(C)C)N2Cc3cccc(N)c3C2=O)ccc1OC

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.49
PDE4A P27815 10/20 0.47
PDE4B Q07343 10/20 0.47
PDE4C Q08493 10/20 0.47
PDE4D Q08499 10/20 0.47
TNF P01375 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.43
ALDH1A1 P00352 1/20 0.42
HTR2B P41595 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3552410 0.91 TP53 (0.51) TP53PDE4APDE4BPDE4CPDE4D
SCHEMBL3558078 0.90 TP53 (0.53) TP53PDE4APDE4BPDE4CPDE4D
Cyclopropane SCHEMBL15252799 0.89 TP53 (0.47) TP53PDE4APDE4BPDE4CPDE4D
SCHEMBL3556554 0.89 TP53 (0.55) TP53PDE4APDE4BPDE4CPDE4D
SCHEMBL3553808 0.88 TP53 (0.51) TP53PDE4APDE4BPDE4CPDE4D
SCHEMBL5516142 0.88 TP53 (0.46) TP53PDE4APDE4BPDE4CPDE4D
SCHEMBL3553524 0.87 TP53 (0.50) TP53PDE4APDE4BPDE4CPDE4D
SCHEMBL537176 0.84 PDE4A (0.52) TP53PDE4APDE4BPDE4CPDE4D
SCHEMBL3557850 0.84 PDE4A (0.54) TP53PDE4APDE4BPDE4CPDE4D
SCHEMBL3554030 0.83 PDE4B (0.59) TP53PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1605896-B1 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2013-09-18 EP claimed
JP-2006519851-A 2006-08-31 JP claimed
US-7034052-B2 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2006-04-25 US claimed
EP-1605896-A2 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-12-21 EP claimed
US-20040254214-A1 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION 2004-12-16 US claimed
WO-2004080423-A2 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2004-09-23 WO claimed
EP-1605896-B1 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2013-09-18 EP disclosed
US-7799819-B2 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2010-09-21 US disclosed
US-20090131505-A1 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses MAN HON-WAH 2009-05-21 US disclosed
US-7511072-B2 7-amido-isoindolyl compounds and methods of its use CELGENE CORPORATION (US) 2009-03-31 US disclosed
US-20070254942-A1 7-amido-isoindolyl compounds and methods of its use CELGENE CORPORATION. 2007-11-01 US disclosed
US-7256210-B2 7-amido-isoindolyl compounds and methods of their use CELGENE CORPORATION (US) 2007-08-14 US disclosed
US-7034052-B2 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2006-04-25 US disclosed
US-20060058362-A1 7-Amido-isoindolyl compounds and methods of their use MAN HON-WAH 2006-03-16 US disclosed
EP-1605896-A2 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-12-21 EP disclosed
US-20040254214-A1 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION 2004-12-16 US disclosed
WO-2004080423-A2 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058362-A1 7-Amido-isoindolyl compounds and methods of their use MCL1, APC, HPGDS TP53 262/4885PDE4A 1516/4885PDE4B 2106/4885
US-20040254214-A1 7-Amido-isoindolyl compounds and their pharmaceutical uses MCL1, APC, THPO TP53 360/4885PDE4A 445/4885PDE4B 729/4885
US-20090131505-A1 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses THPO, MCL1, HPGDS TP53 276/4885PDE4A 576/4885PDE4B 564/4885
US-20070254942-A1 7-amido-isoindolyl compounds and methods of its use MCL1, THPO, APC TP53 192/4885PDE4A 2086/4885PDE4B 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.